Clinical trials in the development of biosimilars: future considerations

References

• EMA Guideline on Similar Biological Medicinal Products, CHMP/437/04, October 30, 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed February 12, 2015.
   Google Scholar
• WHO Guidelines on evaluation of similar biotherapeutic products (SBPs), adopted October 19–23, 2009. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_ FOR_WEB_22APRIL2010.pdf. Accessed February 12, 2015.
   Google Scholar
• FDA biosimilar draft guidances Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm. Accessed February 12, 2015.
   Google Scholar
• US Government Publishing Office [homepage on the Internet]. § 262, Regulation of biological products. Available from: http://www.gpo.gov/fdsys/pkg/USCODE-2010-title42/pdf/USCODE-2010-title42-chap6A-subchapII-partF-subpart1-sec262.pdf. Accessed
   Google Scholar
• McCamish M, Pakulski J, Sattler C, Woollett, G. Toward interchangeable biologics. Clin Pharmacol Ther. 2015; doi: 10.1002/cpt.39.
   Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH) Guideline on Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process Q5E; November 18, 2004. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed February 12, 2015.
   Google Scholar
• PMDA Guideline for the Quality, Safety and Efficacy Assurance of Follow-on Biologics, PFSB/ELD Notification No 0304007, March 4, 2009. Available from: http://www.pmda.go.jp/english/service/pdf/notifications/PFSB-ELD-0304007.pdf. Accessed February 12, 2015.
   Google Scholar
• TGA, Evaluation of biosimilars. Available from: https://www.tga.gov.au/evaluation-biosimilars. Accessed February 12, 2015.
   Google Scholar
• Health Canada, Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs), March 5, 2010. Available from: http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf. Accessed February 12, 2015.
   Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotech. 2011;29(4):310–312.
   PubMed Web of Science ®Google Scholar
• Schneider CK. Biosimilars in rheumatology: the wind of change. Annals Rheum Dis. 2013;72(3):315–318.
   PubMed Web of Science ®Google Scholar
• EMA Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins, CHMP/EWP/89249/2004, January 24, 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003029.pdf. Accessed February, 12 2015.
   Google Scholar
• EMA Annex: Guidance on Similar Medicinal Products Containing Somatropin, EMEA/CHMP/BMWP/94528/2005, February 22, 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003956.pdf. Accessed February 12, 2015.
   Google Scholar
• Omnitrope®: EPAR- Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000607/WC500043692.pdf. Accessed February 12, 2015.
   Google Scholar
• EMA Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, EMEA/CHMP/BMWP/42832/2005 Rev.1, December 18, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Accessed February 12, 2015.
   Google Scholar
• Health Canada Summary basis of decision (SBD) for Omnitrope®. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2009_omnitrope_113380-eng.pdf. Accessed February 12, 2015.
   Google Scholar
• FDA Letter of Approval for Omnitrope®. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021426s000_APPROV.pdf. Accessed February 12, 2015.
   Google Scholar
• Arato T, Yamaguchi T. Experience of reviewing the follow-on biologics including somatropin and erythropoietin in Japan. Biologicals. 2011;39:289–292.
   Web of Science ®Google Scholar
• Biograstim®. EPAR-Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000826/WC500053904.pdf. Accessed February 12, 2015.
   Google Scholar
• Zarzio®. EPAR – Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Public_assessment_report/human/000917/WC500046528.pdf. Accessed February 12, 2015.
   Google Scholar
• Nivestim®. EPAR -Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001142/WC500093664.pdf. Accessed February 12, 2015.
   Google Scholar
• Grastofil®. EPAR -Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002150/WC500154066.pdf. Accessed February 12, 2015.
   Google Scholar
• EMA Guideline on Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor, EMEA/CHMP/BMWP/31329/2005. February 22, 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003955.pdf. Accessed February 12, 2015.
   Google Scholar
• Ratiograstim®. EPAR-Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Public_assessment_report/human/000825/WC500047793.pdf. Accessed February 12, 2015.
   Google Scholar
• Tevagrastim®. EPAR-Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Public_assessment_report/human/000827/WC500036667.pdf. Accessed February 12, 2015.
   Google Scholar
• Filgrastim Hexal®. EPAR-Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000918/WC500022471.pdf. Accessed February 12, 2015.
   Google Scholar
• Accofil®. EPAR-Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003956/WC500176711.pdf. Accessed February 12, 2015.
   Google Scholar
• Nivestim®. Australian Public Assessment Report. Available from: https://www.tga.gov.au/auspar/auspar-filgrastim-0. Accessed February 12, 2015.
   Google Scholar
• Tevagrastim®. Australian Public Assessment Report. Available from: https://www.tga.gov.au/auspar/auspar-filgrastim. Accessed February 12, 2015.
   Google Scholar
• Zarzio®. Australian Public Assessment Report. Available from: https://www.tga.gov.au/auspar/auspar-filgrastim-rbe. Accessed February 12, 2015.
   Google Scholar
• Binocrit®. EPAR-Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf. Accessed February 12, 2015.
   Google Scholar
• Retacrit®. EPAR-Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374.pdf. Accessed February 12, 2015.
   Google Scholar
• EMA Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision); 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf. Accessed February 12, 2015.
   Google Scholar
• Epoetin alfa Hexal®. EPAR-Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000726/WC500028287.pdf. Accessed February 12, 2015.
   Google Scholar
• Abseamed®. EPAR-Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_ Discussion/human/000727/WC500020666.pdf. Accessed February 12, 2015.
   Google Scholar
• Silapo®. EPAR-Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000760/WC500050914.pdf. Accessed February 12, 2015.
   Google Scholar
• Binocrit®-H-C-725-II-06. EPAR-Assessment Report-Variation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000725/WC500053679.pdf. Accessed February 12, 2015.
   Google Scholar
• Epoetin alfa Hexal®-H-C-726-X-10. EPAR-Assessment Report-Variation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000726/WC500028283.pdf. Accessed February 12, 2015.
   Google Scholar
• Abseamed®-H-C-727-II-06. EPAR-Assessment Report-Variation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000727/WC500020660.pdf. Accessed February 12, 2015.
   Google Scholar
• Retacrit®. EPAR-Procedural steps taken and scientific information after authorization. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000872/WC500054376.pdf. Accessed February 12, 2015.
   Google Scholar
• Silpo®. EPAR-Procedural steps taken and scientific information after authorization. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000760/WC500050916.pdf. Accessed February 12, 2015.
   Google Scholar
• Retacrit®-H-C-872-II-36. EPAR-Assessment Report-Variation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000872/WC500116652.pdf. Accessed February 12, 2015.
   Google Scholar
• Epoetin Lambda. Australian Pharmaceutical Benefits Scheme, Public Summary Document. Available from: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2010-07/Epoetin_lambda_NOVICRIT_Novartis2.pdf. Accessed February 12, 2015.
   Google Scholar
• Korean approval of Celltrion’s Infliximab®. Available from: http://www.celltrion.com/en/COMPANY/company02.asp?menu_num=2. Accessed February 12, 2015.
   Google Scholar
• Remsima®. EPAR-Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Accessed February 12, 2015.
   Google Scholar
• Inflectra®. EPAR-Public Assessment Report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Accessed February 12, 2015.
   Google Scholar
• EMA Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed February 12, 2015.
   Google Scholar
• Remsima®. Health Canada Summary Basis of Decision. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_remsima_160195-eng.php. Accessed February 12, 2015.
   Google Scholar
• Inflectra®. Health Canada Summary Basis of Decision. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php. Accessed February 12, 2015.
   Google Scholar
• Japanese approval of Remisma®. Available from: http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2014.pdf. Accessed February 12, 2015.
   Google Scholar